Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study-Reference-Cited by-同舟云学术

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study

Published:2024-02 Issue:2 Volume:12 Page:e282-e291
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Asare Kwabena,Sookrajh Yukteshwar,van der Molen Johan,Khubone Thokozani,Lewis Lara,Lessells Richard J,Naidoo Kogieleum,Sosibo Phelelani,van Heerden Rosemary,Garrett Nigel,Dorward Jienchi

Funder

Bill and Melinda Gates Foundation

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research;Dorward;Lancet HIV,2018

2. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019

3. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV;Paton;N Engl J Med,2021

4. Dolutegravir for second-line treatment: programmatic implications of new evidence;Zhao;South Afr J HIV Med,2022

5. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study;Dorward;Lancet HIV,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three Year Outcomes after Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti;2024-08-14

2. Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis;2024-06-23

3. Dolutegravir for second-line antiretroviral therapy: the beat goes on;The Lancet Global Health;2023-12